EGFR Gene Mutation, EGFR-TKI Resistant Mutation, Non-small Cell Lung Cancer
Conditions
Keywords
nPKC delta, Angiogenesis, EGFR TKI drug resistant
Brief summary
The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
Detailed description
The efficacy of the regimen is evaluated by participants' progression-free survival and overall survival. Nintedanib is a medication that blocks endothelial cells in tumor microenvironments and is effective in delaying tumor progression. Nintedanib is also a drug approved for idiopathic pulmonary fibrosis in the clinic. The participants will take 1 nintedanib tablet after a meal twice per day with a twelve-hour interval. EGFR TKI-gefitinib, erlotinib, afatinib, or osimertinib will be taken 1 tablet once per day during each treatment cycle. The treatment cycle in this study is 30 days. In this study, the participants will have a physical exam in 6 weeks and 12 weeks after the initiation of the treatment. In the 6 weeks of the study, the participants will have blood tests and a CT scan. About 5cc of blood will be collected each time. In addition, the participant's tumor will be measured by a CT scan every 12 weeks. If the participants develop any unacceptable symptoms or changes in liver function tests, the participants' treatment may be delayed and/or the dose decreased until the symptoms are disappeared. It may even be necessary to stop your treatment. The doctor will inform the participant of any changes in the participants' treatment schedule or in the doses of medication after he/she evaluates the participants in the clinic. After treatment ends, the participants will have a follow-up visit at the clinic. At this visit, the participants will have a complete physical exam, including blood (about 5cc) tests and CT scan to measure the size of the tumors. This is an investigational study. Up to 20 participants will take part in this study.
Interventions
DRUGNintedanib, gefitinib, erlotinib, afatinib, osimertinib
Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration. Gefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells.
Sponsors
China Medical University, Taiwan
China Medical University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Participants between 20 to 70 years old, are pathologically confirmed advanced (stage III and IV) non-small cell lung cancer. 2. Positive EGFR mutations are diagenesis. 3. Participants with histologically/cytologically confirmed locally advanced or metastatic adenocarcinoma subtype NSCLC after the failure of first-line EGFR tyrosine kinase inhibitors- gefitinib, erlotinib, afatinib, or osimertinib. 4. Participants must have adequate hepatic, renal, and bone marrow function
Exclusion criteria
1. Participants previously received first-line EGFR tyrosine kinase inhibitor with serious side effects. 2. Participants have known hypertension, and chronic liver and gastrointestinal disease. 3. Participants have known brain metastasis. 4. Female participants who are pregnant or breast-feeding 5. Participants have a known diagnosis of negative nPKCδ expression by immunohistochemistry (IHC).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The toxicity of combinate nintedanib and EGFR TKI | Assessed every 6 weeks of chest CT scan until PD. |
| Patient objective response rate | Assessed every 6 weeks of chest CT scan |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | Assessed every 12 weeks thereafter up to end of study at approximately 2 years |
Countries
Taiwan
Contacts
Primary ContactChih-Yen Tu
Outcome results
None listed